Navigation Links
Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
Date:11/5/2010

cellular matrix. Halozyme's Enhanze™ technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche to apply Enhanze technology to Roche's biological therapeutics, including Herceptin® and MabThera®, for up to 13 targets, and with Baxter BioScience to apply Enhanze technology to immunoglobulin. Halozyme's Ultrafast Insulin program combines its rHuPH20 enzyme with mealtime insulins, which may produce more rapid absorption, faster action, and improved glycemic control. The product candidates in Halozyme's pipeline target multiple areas of significant unmet medical need. For more information visit www.halozyme.com.

Safe Harbor Statement In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning the timing and scope of our clinical trials as well as expected activities under our collaborative partnerships) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including regulatory approval requirements and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the company's reports
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
2. Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
3. Halozyme Therapeutics to Present at Upcoming Investor Conferences
4. Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
5. Halozyme Therapeutics to Host Research Day for Investors and Analysts
6. Halozyme Therapeutics to Present at Upcoming Investor Conferences
7. Halozyme Therapeutics Announces Conference Call on November 6 to Review Third Quarter Results
8. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
9. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
10. Halozyme Receives $5.5 Million Payment From Baxter
11. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 18, 2014 Egenix, Inc. is ... been elected Chairman of the Board, to succeed Donald ... CEO, but will continue as a member of the Board.  ... has added to the company over almost twenty years, the ... The Board of Directors has established a Search Committee to ...
(Date:12/17/2014)... Bellingham, Washington, USA (PRWEB) December 16, 2014 ... Kirstin Baum, manager at Philipps- Universität Marburg’s Department ... optics and photonics, in the newly released ... 2015-2016. “And never be too shy to ask ... STEM (science, technology, engineering, and mathematics) occupations ranging ...
(Date:12/17/2014)... IN (PRWEB) December 17, 2014 ... Laboratory Excellence following its most recent COLA inspection. ... by COLA, a national healthcare accreditation organization. Accreditation ... standards of quality in day-to-day operations, demonstrate continued ... pass a rigorous on-site laboratory survey. ...
(Date:12/17/2014)... , Dec. 17, 2014 CASI Pharmaceuticals, Inc. ... to the acquisition, development and commercialization of innovative therapeutics ... global market with a primary commercial focus on ... been granted a Type C meeting with the U.S. ... will be held in February 2015.  During this meeting ...
Breaking Biology Technology:Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 2Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 3Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5
... complementary technologies to extend, reach into multiple key surgical activities, ... ... Ethicon Endo-Surgery announced,today that it has entered into a ... advanced bipolar tissue sealing system used,in the EnSeal(R) family of ...
... Informed Medical Communications,(IMC), a leading provider of peer-to-peer ... today on recent revisions,to the PhRMA Code. "IMC ... noted Dr. Jaime Nguyen, Medical Director/Compliance Officer,for IMC. ... monitored,the compliance trends so that our services can ...
... /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex:,SVA), a vaccine-focused biotech ... 2007 Annual Meeting of Shareholders on Thursday, September 4,2008 ... held concurrently at,No. 39 Shangdi Xi Road, Haidian District, ... Antigua. All shareholders of record as of August 1,2008 ...
Cached Biology Technology:Ethicon Endo-Surgery to Acquire SurgRx 2Ethicon Endo-Surgery to Acquire SurgRx 3Informed Medical Communications Highlights Opportunity in Revised PhRMA Code 2Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders 2
(Date:12/10/2014)... December 9, 2014   ... Platform   Jifflenow, ... scheduling solutions for business-to-business (B2B) events, today announced ... in mobile near-field communication (NFC), Bluetooth low energy ... (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will integrate ...
(Date:12/4/2014)... BEACH GARDENS, Fla. , Dec. 3, 2014 ... management solutions, today announced that its DigitalPersona ® ... 4500 fingerprint readers have been deployed throughout First ... , South Carolina ... headquartered in Southern Pines, North Carolina ...
(Date:11/21/2014)... November 18, 2014 According to ... by Systems (Video, RFID, Access Control, Intrusion Detection, Parking ... Banks, Government), Component Service Geography - Global Forecasts to ... is projected to be around $25 Billion in 2014 ... growing at a CAGR of 8.69%. Browse ...
Breaking Biology News(10 mins):Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3
... shown that not all individuals carrying the Romanian "Basarab" ... the real-life Dracula, can be direct biological descendants of ... historical and geographical southern region of present-day Romania, for ... Vlad III the Impaler, commonly known as Dracula. The ...
... the Chinese Academy of Sciences have teamed up to create ... systems. Finding more effective and efficient ways to store ... of peak demand on electricity grids. The ability to store ... a pressing problem. People use a wide variety of ...
... National Science Foundation (NSF) has awarded a three-year $999,531 ... used to make custom DNA molecules with the tools ... by Jean Peccoud, Associate Professor at the Virginia Bioinformatics ... Professors in the Grado Department of Industrial and Systems ...
Cached Biology News:'Basarab' surname may not indicate direct relation to Vlad the Impaler 2University of Leeds and Chinese Academy of Sciences join forces 2University of Leeds and Chinese Academy of Sciences join forces 3National Science Foundation awards $1 million to improve the efficiency of DNA fabrication 2
One-step, microplate or cuvet, colorimetric, linear detection range 8 mg/dL to 300 mg/dL. Procedure: 5 min....
Homo sapiens jumping translocation breakpoint...
One-step, microplate or cuvet, colorimetric 530nm, detection limit 0.16mg/dL in serum or plasma. Procedure: 10 min....
MOUSE ANTI HUMAN NPM...
Biology Products: